A Study to Test How BI 764532 is Taken up by Tumours in People With Small-cell Lung Cancer or Neuroendocrine Cancer

Exclusion Criteria

• •Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
• •At least one evaluable lesion outside of Central Nervous System (CNS) as defined per Response Evaluation Criteria in Solid Tumours (RECIST) 1.1
• •Subjects with brain metastases are eligible provided they meet the following criteria:
• •* radiotherapy or surgery for brain metastases was completed at least 2 weeks prior to the first administration of BI 764532,
• •* patient is off steroids for at least 7 days (physiologic doses of steroids are permitted), and the patient is off anti-epileptic drugs for at least 7 days or on stable doses of anti-epileptic drugs for malignant CNS disease.
• •Previous or concomitant malignancies other than the one treated in this trial within the last 2 years except:
• •* effectively treated non-melanoma skin cancers
• •* effectively treated carcinoma in situ of the cervix
• •* effectively treated ductal carcinoma in situ
• •* other effectively treated malignancy that is considered cured by local treatment
• •Major injuries and/or surgery or bone fracture within 28 days of first dose BI 764532, or planned surgical procedures
• •Known leptomeningeal disease or spinal cord compression due to metastatic disease
• •Anticoagulant treatment that cannot be safely interrupted based on opinion of the investigator if medically needed
• •Active infection that requires medical therapy or other clinically significant intervention
• •Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection within 2 weeks prior to study entry (confirmed via polymerase chain reaction (PCR) test or other applicable test as per local requirements) or suspected SARS-CoV-2 infection as per physician assessment, or close contact (within 1 week) with an individual with confirmed SARS-CoV-2 infection
• •Any of the following known laboratory evidence of hepatitis virus infection:
• •* Positive results of hepatitis B surface (HBs) antigen
• •* Presence of hepatitis B core (HBc) antibody together with hepatitis B virus DNA (HBV-DNA)
• •* Presence of hepatitis C ribonucleic acid (RNA)